大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践

doi:10.19803/j.1672-8629.2022.04.22

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 446-449.
DOI: 10.19803/j.1672-8629.2022.04.22

大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践

陈方方, 张红旭^*

徐州市肿瘤医院药剂科,江苏徐州 221005

收稿日期:2020-06-01 出版日期:2022-04-15 发布日期:2022-04-15
通讯作者: ^*张红旭,男,硕士,主任药师,临床药学研究。E-mail：wastlx@163.com
作者简介:陈方方,女,在读硕士,主管药师,医院药学。
基金资助:
国家重点研发计划（2018YFC1707405）

Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate

CHEN Fangfang, ZHANG Hongxu^*

Department of Pharmacy, Xuzhou Tumor Hospital, Xuzhou Jiangsu 221005, China

Received:2020-06-01 Online:2022-04-15 Published:2022-04-15

摘要/Abstract

摘要： 目的研究原发性中枢神经系统淋巴瘤（PCNSL）患者大剂量甲氨蝶呤（HD-MTX）治疗过程中的临床药学实践方法。方法以1例HD-MTX治疗PCNSL患者为例,临床药师运用药学专业知识主动参与临床治疗,协助医师制定化疗及解救方案,对患者开展药学监护,进行个体化的药学服务,保证患者药物治疗安全、有效。结果患者药物治疗安全、有效,过程顺利。结论临床药师可以在临床药物治疗过程中发挥作用,促进临床药物治疗水平,确保患者用药安全、有效。

关键词: 原发性中枢神经系统淋巴瘤, 甲氨蝶呤, 临床药师, 合理用药, 药学服务

Abstract: Objective To study the clinical pharmaceutical practice in the process of treating primary central nervous system lymphoma (PCNSL) with high dose methotrexate (HD-MTX). Methods One patient with PCNSL was treated with HD-MTX. The clinical pharmacist took active part in the clinical treatment of this patient using pharmaceutical knowledge, assisted doctors in formulating chemotherapy and rescue plans, gave pharmaceutical care to this patient, and provided individualized pharmaceutical service to ensure the safety and effectiveness of medication. Results Drug treatment of this case of PCNSL was safe, effective and smooth. Conclusion Clinical pharmacists can play a role in the process of clinical drug treatment, improve the level of clinical drug treatment, and ensure the safety and effectiveness of drug use.

Key words: primary central nervous system lymphoma, methotrexate, clinical pharmacist, rational drug use, pharmaceutical serve

中图分类号:

R969.3

陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.

CHEN Fangfang, ZHANG Hongxu. Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.

参考文献

[1] LI XY, FENG JF.Treatment of primary central nervous system lymphoma[J]. Journal of International Oncology(国际肿瘤医学杂志), 2016, 43(1): 71-74.
[2] YU Y, GAO XG.Progress in diagnosis and treatment of primary central nervous system lymphoma[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2019, 26(16): 1145-1149.
[3] LI YJ, LIU YT, ZHOU H.Rituximab with high-dose methotrexate in primary central nervous system lymphoma[J]. The Journal of Evidence-Based Medicine(循证医学), 2018, 18(2): 78-82.
[4] Chinese Society of Clinical Oncology, Anti Leukemla Alliance of Chinese Society of Clinical Oncology. Expert consensus on high dose methotrexate calcium folinate rescue therapy for malignant tumor[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(15): 761-767.
[5] Cancer Clinical Chemotherapy Committee of China Anti-cancer Association, Cancer Support Therapy Committee of China Anti-cancer Association. Chinese expert consensus on prevention and treatment of malignant vomiting related to tumor drug therapy(2014)[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2014, 19(3): 263-273.
[6] Chinese Society of Clinical Oncology, Chinese Society of Hemato-logy, Oncologist Assessment Committee of Chinese Medical Association. Chinese expert consensus on prevention and treatment of HBV reactivation in lymphoma immunochemotherapy[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2013, 18(10): 935-942.
[7] JIANG FL, SHI WJ, LUAN F, et al.Clinical research on HBV reactivation after TP chemotherapy in patients with gynecologic tumors with HBsAg(-) and HBcAb(+)[J]. China Modern Doctor(中国现代医生), 2016, 54(12): 81-84.
[8] LI YJ, JIANG WQ, LI S, et al.A study to compare the pharmaco-dynamics and pharmacokinetics of two regimens of high-dose methotrexate in patients with lymphoma[J]. The Practical Journal of Cancer(实用癌症杂志), 2010, 25(2): 153-157.
[9] XU WQ, TANG YM, FANG CQ, et al.Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia[J]. Chinese Journal of Hematology(中华血液学杂志), 2015, 26(1): 15-18.
[10] ZHU TT, ZHAO YL, FENG LY, et al.Research progress on the influe-ncing factors and mechanism of elimination delay after high-dose methotrexate chemotherapy[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2017, 25(1): 49-54.
[11] LAI R, YANG RR.TDM of High dose methotrexate in the treatment of adult diffuse large B-cell lymphoma[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2019, 12(10): 65-66.
[12] HE HL, LI G, LI J, et al.Application of blood concentration monitoring in childhood acute lymphoblastic leukemia treated with high-dose methotrexate[J]. Practical Journal of Clinical Medicine(实用医院临床杂志), 2016, 9(3): 74-77.
[13] WU W, YAO DF, XU Q.Clinical pharmacist’s involvement in treatment of delayed excretion of large doses of methotrexate in post-drug period: case analysis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2017, 14(8): 741-743.
[14] HUANG L, XU YJ, FENG WY.Pharmaceutical practice of clinical pharmacists participating in rescue treatment of large dose methionine poisoning[J]. China Pharmacy(中国药房), 2016, 24(46): 4399-4401.

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	黎杏仁, 沈爱宗, 苏丹. 质子泵抑制剂预防胆胰外科围术期应激性黏膜病变的合理性评价[J]. 中国药物警戒, 2023, 20(9): 1022-1026.
[4]	史香芬, 孙志勇, 张旭锋, 卢晓静, 杜书章, 张晓坚. 基于智能信息管理系统的门诊麻精药品全流程管理[J]. 中国药物警戒, 2023, 20(8): 899-903.
[5]	霍艳飞, 田月洁, 许莉莉, 谢彦军, 常虹, 孙春晓, 李霞. 535例氢溴酸高乌甲素制剂新的和严重的药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(8): 921-926.
[6]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[7]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[8]	王然, 冯欣, 杜博冉. 围孕期妊娠用药暴露风险评价与药学实践进展[J]. 中国药物警戒, 2023, 20(7): 836-840.
[9]	罗芳梅, 吴攀, 李静, 王婷, 王方杰. ABCB1 C3435T基因多态性与成熟B细胞淋巴瘤患儿大剂量甲氨蝶呤血药浓度和不良反应的相关性研究[J]. 中国药物警戒, 2023, 20(6): 675-679.
[10]	范秀丛, 董晓慧, 陈丹霞, 鲍思蔚, 马雅斌. 1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护[J]. 中国药物警戒, 2023, 20(5): 579-582.
[11]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[12]	殷进军, 王淑伟, 邵姜超, 王冰. 基于加权TOPSIS法的贝伐珠单抗注射液药物利用评价[J]. 中国药物警戒, 2023, 20(12): 1421-1426.
[13]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[14]	刘斌, 邵美玲, 蔡怡然, 马丰懿, 兰鸿. 戴明环循环管理在提高门诊处方合理率中的应用价值[J]. 中国药物警戒, 2022, 19(9): 1035-1039.
[15]	庄红艳, 臧彦楠, 刘珊珊, 牛梦溪, 房萌, 尹冬青, 果伟. 唑吡坦致神经精神系统不良反应分析[J]. 中国药物警戒, 2022, 19(8): 889-892.

大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践

Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics